RiboBio Unveils Breakthrough in Kidney-Targeted siRNA Delivery at ASN Kidney Week

Recently,"Ribo Life Science"At the ASN Kidney Week held in Texas, USAAnnounced an important research achievement：Achieve Kidney-Specific Targeted Delivery of siRNA Through the Self-Developed RiboPepSTAR™ Conjugation Technology. The studyFurther validates the technical advantages of Ribo Life Science's kidney-targeting platform.——Enables precise silencing of target genes in specific cell types of the kidney, opening a new avenue for the treatment of chronic kidney disease (CKD).

Preclinical Study DataThe delivery system demonstrated efficacy across species models, ranging from rodents to non-human primates (NHP).Both achieved specific uptake by proximal tubular cells, with target gene silencing efficiency reaching up to 80%.Moreover, in rodent models of type 2 diabetes and CKD, highly efficient and specific silencing of relevant target genes in kidney tissues was achieved whileSignificant improvement in corresponding efficacy indicators was also observed.。

Chronic kidney disease still has huge unmet clinical needs, and this breakthrough technology brings new hope to the field of kidney disease treatment. By precisely targeting specific kidney cell types, it is expected to develop more targeted and effective siRNA innovative therapies. Ribo Life Science will accelerate its translation into clinical applications, providing new treatment options for over 850 million chronic kidney disease patients worldwide.